Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs that modulate cortisol effects to treat severe endocrinologic, metabolic, oncologic, and neurologic disorders. Its flagship product, Korlym, is a cortisol receptor blocker used to control hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for it. The company advances a pipeline of selective cortisol modulators, including relacorilant, targeting conditions such as hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS), and liver disease. Operating in the health technology sector, specifically pharmaceuticals, Corcept Therapeutics Incorporated addresses unmet needs in rare and serious disorders through innovative therapies that mitigate excess cortisol's adverse impacts. Founded in 1998 and headquartered in Redwood City, California, it plays a key role in advancing treatments for cortisol-related pathologies.